Looking for some interesting healthcare stocks with strong prospects? We ran a screen with that idea in mind.
We began by screening the drug-maker industry of the healthcare sector for stocks rallying above their 20-day, 50-day, and 200-day moving averages, indicating that these stocks have strong upward momentum.
We then screened for those with the confidence of their company insiders, including members of the board and upper management, with significant net insider purchases over the last six months representing at least 2% of the company's share float. Since most companies have only a handful of insiders, net purchases representing over 2% of share float is a big show of confidence.
For an interactive version of this chart, click on the image below. Analyst ratings sourced from Zacks Investment Research.
Tool provided by Kapitall (kapitall.com).
Do you think these stocks will continue to rally higher? Use this list as a starting point for your own analysis.
List sorted by net insider purchases as a percent of share float.
1. Ardea Biosciences, Inc. (RDEA): Focuses on the discovery and development of small-molecule therapeutics for the treatment of gout and cancer in the United States. Market cap at $1.18B, most recent closing price at $31.98. The stock is currently trading 0.07% above its 20-day moving average, 7.49% above its 50-day MA, and 50.47% above its 200-day MA. Over the last six months, insiders were net buyers of 1,285,338 shares, which represents about 6.31% of the company's 20.36M share float.
2. Pharmacyclics Inc. (PCYC): Operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. Market cap at $2.8B, most recent closing price at $40.52. The stock is currently trading 30.28% above its 20-day moving average, 53.28% above its 50-day MA, and 129.50% above its 200-day MA. Over the last six months, insiders were net buyers of 2,054,434 shares, which represents about 3.77% of the company's 54.51M share float.
3. Pacira Pharmaceuticals Inc. (PCRX): Engages in the development, commercialization, and manufacture of pharmaceutical products for hospitals and ambulatory surgery centers. Market cap at $450.54M, most recent closing price at $13.94. The stock is currently trading 27.25% above its 20-day moving average, 39.31% above its 50-day MA, and 57.73% above its 200-day MA. Over the last six months, insiders were net buyers of 511,422 shares, which represents about 2.8% of the company's 18.27M share float.
*Insider data sourced from Yahoo! Finance, all other data sourced from Finviz.